Viewpoints

As Russia’s invasion of Ukraine continues, industry leaders speak out in condemnation of the actions taking place and pledge to provide aid to those in need.

As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.

The process of reshaping inevitably leads to fresh insights.

An obvious theme for 2021 has been COVID-19, but the next 12 months will see industry and its people experiencing further change.

Overall, 2021 proved to be another good year for drug approvals in Europe, albeit with a slight disappointment for Alzheimer’s patients, but what should industry be watching out for in 2022?

Pharma and biotech are ruling the roost in terms of university innovation, but European spinouts are still experiencing barriers to long-term success.

Manufacturing capacity expansion is high on the agenda for many bio/pharma companies and service providers in Europe.

Change of roster does not change the goal line. We are all patients first.

While the players may change, pharma’s patients-first focus should not.

Excessive drug pricing is being scrutinized across Europe, as hefty fines are set to send out a clear message of intolerance to anti-competition conduct.

The root cause of the most serious integrity issues has generally been a lapse of ethical behavior on the part of an individual.

GSK’s position is raising concerns as it continues working towards its separation of businesses.

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates.

Technology advances foster new therapies.

As face masks start to come off, bio/pharma’s COVID-19 battle goes on.

The world of bio/pharma has been celebrating its achievements across a variety of categories in the latest rounds of awards.

COVID-19 has placed bio/pharma in the spotlight of global media, but away from vaccines there are other prospective pipeline treatments that will be worth watching.

Bio/pharma works hard today to change the calendar to tomorrow.

More work is needed to ensure the rising demand for cell and gene therapy manufacturing capacity and required skilled workforce can be met in Europe.

More work is needed to educate businesses on the value of innovation and the availability of funding.

COVID-19 vaccine supplies are breaking news headlines, in both ‘good’ and ‘not so good’ ways.

Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, commends the leadership of the pharmaceutical industry in combatting the COVID-19 pandemic.

A complicated vaccination rollout and mixed messages may derail the pandemic endgame.

The outlook for the European pharma industry is appearing to be favourable overall.

Industry wants clarification on compliance following the end of the Brexit transition period.

Resolving drug shortages starts with identifying the source of the problem.

The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.

The case for migrating from a paper-based quality management system to a digital platform is presented.

European pharma companies may have a vested interest in the outcome of the US elections.

AstraZeneca has potentially taken poll position in the race to develop a novel coronavirus vaccine, but will AZD1222 be ready in 2020?